[Dose optimization in clinical oncology: pharmacokinetic-pharmacodynamic relationship].
The establishment of relationships between pharmacokinetics and pharmacodynamics of anticancer drugs might allow to individualize the dosing of these drugs. Our knowledge of this kind of relationship has grown markedly in recent years. After a review of the different causes of variability in pharmacokinetics and pharmacodynamics of these drugs, the different models used for establishing these correlations were analyzed and criticized. Finally, the three methods for adapting drug dosing based on pharmacokinetic data were proposed and the main applications of these concepts were reviewed.
Canal
P
P
Groupe de pharmacologie clinique et expérimentale des médicaments anticancéreux, université Paul-Sabatier, Toulouse, France.
Chatelut
E
E
D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D006801:Humans; D008657:Metabolic Clearance Rate; D015233:Models, Statistical; D009369:Neoplasms / Q000188:drug therapy*; D014018:Tissue Distribution
D000970:Antineoplastic Agents
Optimisation de dose en oncologie clinique. Relation pharmacocinétique-pharmacodynamie.